Study mapping genetic and environmental links of anti-PC published in Atherosclerosis
(Thomson Reuters ONE) -
Solna, Sweden, 30 May 2011 - Scientists suggest an independent role of anti-PC
as a biomarker in cardiovascular disease in a study just published on-line in
Atherosclerosis. The testing was performed using Athera Biotechnologies
CVDefine® kit.
Previous studies have reported that low levels of anti-PC are linked to
development of atherosclerosis and serious cardiovascular consequences like
heart attack and stroke. This study measured anti-PC levels in samples from
2036 elderly twins, with an observed heritable component of 40%. This may help
to explain the strong genetic impact on cardiovascular risk.
"We are already developing a therapeutic antibody for prevention of secondary
cardiovascular events in myocardial infarction patients with low levels of anti-
PC. These new findings indicate that the novel biomarker anti-PC can provide
information on atherosclerotic progression not already captured by other
established biomarkers", says Carina Schmidt, CEO of Athera.
About Athera Biotechnologies AB (publ)
Athera has a unique and in-depth understanding of the immunological components
in atherosclerosis, the inflammatory process leading to cardiovascular disease
(CVD). The company currently has two biopharmaceutical product candidates aimed
at treating patients with cardiovascular conditions and a biomarker linked to
the therapeutic approach.
PC-mAb from Athera is currently in pre-clinical development, using a unique
fully human monoclonal antibody. PC-mAb is being developed to restore cardio-
protective levels of anti-PC and prevent secondary CVD events after acute
coronary syndrome.
In addition, Athera has developed a biomarker and companion diagnostic CVDefine®
kit. The biomarker, anti-PC, is linked to increased risk for cardiovascular
disease and could in the future be used for identification of patients that
benefit from Athera's novel therapeutics.
Athera, a Swedish company, is part of the Karolinska Development AB (publ)
portfolio. www.athera.se
For further Information:
Athera Biotechnologies AB (publ)
Chief Executive Officer
Carina Schmidt
Tel +46 761938190
c.schmidt(at)athera.se
News Release as PDF:
http://hugin.info/143298/R/1519804/456265.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Athera Biotechnologies AB via Thomson Reuters ONE
[HUG#1519804]
Unternehmensinformation / Kurzprofil:
Datum: 30.05.2011 - 15:16 Uhr
Sprache: Deutsch
News-ID 55119
Anzahl Zeichen: 3161
contact information:
Town:
Solna
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 234 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Study mapping genetic and environmental links of anti-PC published in Atherosclerosis"
steht unter der journalistisch-redaktionellen Verantwortung von
Athera Biotechnologies AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
